A study to investigate the efficacy and safety of rilzabrutinib in adult participants with Graves’ disease

Trial Identifier: PDY18663
Sponsor: Sanofi
Start Date: September 2025
Primary Completion Date: August 2026
Study Completion Date: September 2026
Condition: Hyperthyroidism

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

No documents have been posted yet.

Trial Locations

Country Location
CANADA, Alberta Calgary, Alberta, CANADA, T2N 4L7
CANADA, British Columbia Surrey, British Columbia, CANADA, V3T 4G8
CANADA, Quebec Sherbrooke, Quebec, CANADA, J1H 5N4
GERMANY Essen, GERMANY, 45147
GERMANY Frankfurt, GERMANY, 60590
ITALY, Milano Milan, Milano, ITALY, 20122
ITALY, Palermo Palermo, ITALY, 90127
ITALY, Pisa Pisa, ITALY, 56126
SPAIN, Catalunya [Cataluña] Barcelona, Catalunya [Cataluña], SPAIN, 08036
SPAIN, Navarra Pamplona, Navarra, SPAIN, 31008
SPAIN, Sevilla Seville, Sevilla, SPAIN, 41009
UNITED KINGDOM, Buckinghamshire Milton Keynes, Buckinghamshire, UNITED KINGDOM, MK6 5LD
UNITED KINGDOM, England Newcastle Upon Tyne, England, UNITED KINGDOM, NE2 4HH